Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives Overall survival benefit.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
The new credit facility consists of a $7 million term loan and a $5 million revolving line of credit. The line of credit has a two-year term and may be repaid and reborrowed at any time until its maturity date. “We are pleased to obtain this new financing from Bridge Bank during this period of unprecedented economic impact from the global coronavirus pandemic,” said Michael Klein, Chairman and CEO of iCAD.
Educational awareness forum to feature leading experts in discussions on risk adaptive tools and pragmatic solutions to enhance patient care during COVID-19 pandemic Event.
NASHUA, N.H., Jan. 13, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Nathaniel Dalton was appointed to its Board of Directors. Mr. Dalton is one of the founders of the global asset management firm Affiliated Managers Group, Inc. (AMG), where he remains a Director and Senior Advisor. Mr. Dalton held a range of executive positions at AMG, including General Counsel, Chief Operating Officer, President and Chief Executive Officer.
iCAD, Inc.'s (NASDAQ:ICAD): iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early...
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives Conference Call Today at 4:30 p.m. ET.
NASHUA, N.H., April 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (ICAD) today announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500 shares of the Company’s common stock at $8.00 per share, pursuant to a registered direct offering. The Company intends to use the net proceeds for working capital and for other general corporate purposes, including for the conduct of post-market studies for the Company’s Xoft intra-operative radiation therapy (IORT) for glioblastoma and other brain cancers. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-235887) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and made effective on January 31, 2020.
Q4 2019 ICAD Inc Earnings Call
NASHUA, N.H. , May 05, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.
Anyone researching iCAD, Inc. (NASDAQ:ICAD) might want to consider the historical volatility of the share price...
Q1 2020 ICAD Inc Earnings Call
NASHUA, N.H., Feb. 12, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.
NASHUA, N.H., Feb. 11, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the.
One thing we could say about the analysts on iCAD, Inc. (NASDAQ:ICAD) - they aren't optimistic, having just made a...
NASHUA, N.H., Feb. 13, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.
NASHUA, N.H., Feb. 13, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.
NASHUA, N.H., Jan. 27, 2020 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it.
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment Conference call today at 4:30 p.m. ET NASHUA, N.H., Feb. 27,.
ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog Xoft breast IORT offers single-fraction.